Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study of Ompenaclid Versus Placebo in Combination With FOLFIRI Plus Bevacizumab in Patients With Previously Treated RAS Mutant Advanced or Metastatic Colorectal Cancer

NCT05983367 is registered in ClinicalTrials.gov with Inspirna, Inc. as lead sponsor.

NCT NCT05983367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05983367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study of Ompenaclid Versus Placebo in Combination With FOLFIRI Plus Bevacizumab in Patients With Previously Treated RAS Mutant Advanced or Metastatic Colorectal Cancer
Lead sponsor
Inspirna, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 10, 2023
Completion date
March 31, 2025
Enrollment
76 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, metastatic colon cancer